Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Methoxy polyethylene glycol-epoetin beta (Mircera®) is recommended as an option for use within NHS Wales for the treatment of adults with symptomatic anaemia associated with chronic kidney disease. AWMSG is of the opinion that methoxy polyethylene glycol-epoetin beta (Mircera®) is suitable for shared care within NHS Wales |
||
|
||
Medicine details |
||
| Medicine name | methoxy polyethylene glycol-epoetin beta (Mircera®) | |
| Formulation | solution for injection | |
| Reference number | 200 | |
| Indication | Treatment of symptomatic anaemia associated with chronic kidney disease |
|
| Company | Roche Products Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Recommended | |
| Advice number | 1809 | |
| NMG meeting date | 16/09/2009 | |
| AWMSG meeting date | 14/10/2009 | |
| Ratification by Welsh Government | 03/11/2009 | |
| Date of issue | 06/11/2009 | |